Arexera Therapeutics is a preclinical biotechnology company develooping small interfering RNA (siRNA) medicines for severe neurological diseases.  The Company’s proprietary divalent siRNA (di-siRNA) and bispecific siRNA (bi-siRNA) platforms are designed to enable robust and durable gene silencing throughout the brain, including deep brain regions that have historically been difficult to reach. The lead program ATL-101 targets Huntington’s disease.